Q2 2025 saw continued progress in vaccine development, with positive preclinical results and regulatory support for clinical trials. Financially, grant income and a successful share issue strengthened liquidity, while operating losses persisted.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.